A pragmatic starting point for any discussion on longevity is deceptively simple: don’t die. From a clinical perspective, this requires an unflinching focus on the principal drivers of mortality. These are well-established: atherosclerotic cardiovascular disease (including myocardial infarction, stroke, aneurysmal disease, and peripheral arterial disease), cancer, neurodegenerative disorders, and type 2 diabetes with its associated metabolic dysfunction.

Photobiomodulation (PBM) has emerged as a biologically plausible and increasingly evidence-supported intervention that targets several modifiable physiological domains implicated across these disease categories. Clinical studies demonstrate that PBM can enhance exercise capacity, improve sleep quality, reduce nocturnal hypertension, and attenuate systemic oxidative and inflammatory burden, including reductions in C-reactive protein and related biomarkers. Each of these factors is independently associated with cardiovascular risk, metabolic health, and long-term survival.

Beyond these effects, PBM has been shown to improve autonomic balance—as reflected by reductions in resting heart rate and increases in heart rate variability, and to increase VO₂max, a powerful and well-validated predictor of all-cause mortality. Improvements in muscular strength and recovery further support its relevance within a longevity framework that prioritises functional capacity alongside disease prevention.

This presentation will review the mechanistic rationale and clinical evidence underpinning these observations, drawing on a combination of randomised controlled trials and high-quality non-randomised studies. The objective is not to position PBM as a panacea, but to evaluate its potential role as an adjunctive, system-level intervention addressing shared biological pathways across the major causes of age-related morbidity and mortality.